NIOX Group plc has confirmed that as of 31 December 2025 its issued share capital consists of 417,896,847 ordinary shares, each carrying one voting right, with no shares held in treasury. The updated ...

UK biotech Circassia has finally given up on its allergy drug development business, citing difficulties in overcoming a strong placebo effect in the trials required for approval by regulators. After a ...

The UK biotech company is putting its huge failure in allergy treatment behind it with a new deal with AstraZeneca (AZ). But British venture capital leader David Grainger is highly critical of the ...

With the business potentially at an important milestone, we thought we'd take a closer look at Circassia Group Plc's (LON:CIR) future prospects. Circassia Group Plc, a medical device company, focuses ...

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble By Paul Sandle LONDON (Reuters) - Britain's Circassia has secured the U.S. rights from ...

OXFORD, England, January 19 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell ...

- Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ...

Every investor in Circassia Group Plc (LON:CIR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...

OXFORD, England, September 11, 2012--Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann ...

Circassia Ltd., an Oxford, England-based drug company focused on controlling immune system responses, has raised Gbp11 million in second-round funding. Goldman Sachs and Invesco Perpetual were joined ...